Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity

E-ISSN： 2212-4071|7|2|104-110

ISSN： 1574-891X

Source： Recent Patents on Anti-Infective Drug Discovery, Vol.7, Iss.2, 2012-08, pp. : 104-110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

By Drevs J.

Angiogenesis, Vol. 7, Iss. 4, 2004-12 ,pp. : 347-354

Springer Publishing Company

Access to resources Recommend Favorite

Past, Present, and Future of Entry Inhibitors as HIV Microbicides

Current HIV Research, Vol. 10, Iss. 1, 2012-01 ,pp. : 19-26

Bentham Science Publishers

Access to resources Recommend Favorite

The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth

By Shushan Asher

Human Reproduction, Vol. 19, Iss. 9, 2004-09 ,pp. : 1957-1967

Oxford University Press

Access to resources Recommend Favorite

Effects of the Tyrosine Kinase Inhibitor Imatinib on Neuroendocrine Tumor Cell Growth

Digestion, Vol. 71, Iss. 3, 2005-06 ,pp. : 131-140

Karger

Access to resources Recommend Favorite

Nitric oxide synthase inhibitors in cardiogenic shock: present and future

By Kaluski Edo Uriel Nir Milo-Cotter Olga Klapholz Marc

Future Cardiology, Vol. 4, Iss. 2, 2008-03 ,pp. : 183-189

Future Medicine

Access to resources Recommend Favorite